| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/SJ.CGT.7700823 |
| P698 | PubMed publication ID | 15746945 |
| P50 | author | Kah-Whye Peng | Q88612764 |
| Mark J. Federspiel | Q117250257 | ||
| Rae M Myers | Q117250263 | ||
| Suzanne M Greiner | Q117250264 | ||
| Marie Frenzke | Q117250277 | ||
| Diane Soeffker | Q117250278 | ||
| Stephen J. Russell | Q53843820 | ||
| P2093 | author name string | Shmuel Rozenblatt | |
| Alan Shaw | |||
| Mary Harvey | |||
| Katalin Abraham | |||
| P2860 | cites work | The human CD46 molecule is a receptor for measles virus (Edmonston strain) | Q24317745 |
| SLAM (CDw150) is a cellular receptor for measles virus | Q28145297 | ||
| Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster | Q28304963 | ||
| Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. | Q53942590 | ||
| Milky spots in the mouse omentum may play an important role in the origin of peritoneal macrophages | Q68036735 | ||
| Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats | Q74062512 | ||
| Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides | Q78029156 | ||
| Cancer statistics, 2004 | Q29620739 | ||
| Occurrence of sialic acids in healthy humans and different disorders | Q33650215 | ||
| Immune evasion of tumor cells using membrane-bound complement regulatory proteins | Q33774245 | ||
| Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage | Q33835693 | ||
| Targeting adenovirus | Q33837127 | ||
| Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter | Q34275294 | ||
| Replication-selective virotherapy for cancer: Biological principles, risk management and future directions | Q34297058 | ||
| Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection | Q34388037 | ||
| Oncolytic viruses: programmable tumour hunters | Q34729652 | ||
| Selectively replicating adenoviruses for oncolytic therapy | Q34790485 | ||
| RNA viruses as virotherapy agents | Q35043090 | ||
| Oncolytic viruses for the therapy of brain tumors and other solid malignancies a review | Q35109527 | ||
| Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors | Q35197931 | ||
| First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer | Q35226243 | ||
| Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology? | Q35571358 | ||
| Vectors based on autonomous parvoviruses: novel tools to treat cancer? | Q35673377 | ||
| Apoptosis as a cause of death in measles virus-infected cells | Q35840507 | ||
| Replication-selective oncolytic viruses in the treatment of cancer. | Q35912403 | ||
| Evaluation of a neonatal rat model for prediction of mumps virus neurovirulence in humans | Q39585235 | ||
| High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus | Q40534840 | ||
| Antibody-targeted cell fusion | Q40584431 | ||
| Complement-regulatory proteins in ovarian malignancies | Q41135107 | ||
| Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains | Q41482147 | ||
| Treatment of human cancer with mumps virus | Q42439769 | ||
| Milky spots of the omentum: a source of peritoneal cells in the normal and stimulated animal | Q42482517 | ||
| Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system | Q42817129 | ||
| Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas | Q43599287 | ||
| Neurovirulence of mumps virus: intraspinal inoculation test in marmosets | Q45552514 | ||
| Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses | Q45886201 | ||
| P433 | issue | 7 | |
| P921 | main subject | ovarian cancer | Q172341 |
| mumps | Q176741 | ||
| measles vaccine | Q6804161 | ||
| measles | Q79793 | ||
| P304 | page(s) | 593-599 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Cancer Gene Therapy | Q15763088 |
| P1476 | title | Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer | |
| P478 | volume | 12 |
| Q39955752 | A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon |
| Q38212137 | Antitumor Virotherapy by Attenuated Measles Virus (MV). |
| Q64077015 | Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells |
| Q33713865 | Converting tumor-specific markers into reporters of oncolytic virus infection |
| Q37324179 | Engineering oncolytic measles virus to circumvent the intracellular innate immune response |
| Q36373017 | Fighting cancer with oncolytic viruses |
| Q36378886 | Gene therapy for malignant mesothelioma: beyond the infant years |
| Q36464907 | Gene transfer approaches for gynecological diseases |
| Q66680337 | Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus |
| Q37352017 | Inactivated Sendai virus strain Tianjin, a novel genotype of Sendai virus, inhibits growth of murine colon carcinoma through inducing immune responses and apoptosis |
| Q38804011 | Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing |
| Q28072097 | Measles to the Rescue: A Review of Oncolytic Measles Virus |
| Q37388577 | Measles virus for cancer therapy |
| Q37455627 | Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model |
| Q35216344 | Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity |
| Q35861936 | Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency |
| Q35861933 | Oncolysis by paramyxoviruses: preclinical and clinical studies. |
| Q56892727 | Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors |
| Q36318189 | Oncolytic adenoviruses - selective retargeting to tumor cells |
| Q37126088 | Oncolytic myxoma virus: the path to clinic |
| Q35597082 | Oncolytic virotherapy for ovarian cancer |
| Q37641495 | Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. |
| Q37818831 | Oncolytic virotherapy of gynecologic malignancies |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q47552296 | Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA Damaging Agents: Implications for Oncolytic Virus Therapy |
| Q45418761 | Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model |
| Q36315580 | Recent progress in the battle between oncolytic viruses and tumours |
| Q64075125 | Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines |
| Q34707959 | Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers |
| Q28069519 | The Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) Protein |
| Q37810599 | Use of attenuated paramyxoviruses for cancer therapy |
| Q33820717 | Viral oncolysis - can insights from measles be transferred to canine distemper virus? |
| Q35515080 | Viral vector-based therapeutic cancer vaccines |
| Q36850878 | Viruses as anticancer drugs |
Search more.